The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Results: Thirteen patients received a ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) Urologists treating eligible high-risk bladder cancer patients at ...

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty ...

Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...

5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH). Use of 5α-reductase inhibitors (5-ARIs) prior to a bladder cancer ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.